MetaCap

Werewolf Therapeutics (HOWL) vs RenovoRx (RNXT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

RenovoRx (RNXT) has outperformed Werewolf Therapeutics (HOWL) over the past year, gaining 18.3% versus a gain of 8.4%. Over five years, RNXT leads with a -85.3% price change compared with -93.7% for HOWL. Werewolf Therapeutics is the larger company by market cap ($46.0 million vs $45.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HOWL+8.43%RNXT+18.34%
+231%+76%-79%
Nov 21, 20251 yearNov 20, 2026
HOWL-94.08%RNXT-85.71%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HOWL versus RNXT key metrics
MetricHOWLRNXT
Share price$0.9466$0.942
Market cap$46.00M$45.45M
1-day change-3.97%-10.29%
YTD return+49.31%+12.14%
1-year return+8.43%+18.34%
5-year return-93.68%-85.26%
EPS (TTM)$-0.58$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.12M
Revenue growth (YoY)—+2511.63%
Net income (latest FY)$-60.82M$-11.17M
Gross margin—70.88%
Operating margin—-1113.98%
Net margin—-994.48%
52-week high$1.20$2.59
52-week low$0.27$0.77
Distance from 52-week high-21.12%-63.63%
Analyst consensusnonenone
Avg. price target upside+639.49%+656.90%
Average volume1.08M815.75K
Shares outstanding48.60M48.25M
Employees3917
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Werewolf Therapeutics

HOWL stock →

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

About RenovoRx

RNXT stock →

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

HOWL vs RNXT FAQ

Which is bigger, Werewolf Therapeutics or RenovoRx?

Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $46.00M compared with $45.45M for RenovoRx (RNXT).

Which stock has performed better over the past year, HOWL or RNXT?

RNXT returned +18.34% over the past 12 months, compared with +8.43% for HOWL (price return, excluding dividends). Past performance does not predict future results.

Are Werewolf Therapeutics and RenovoRx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons